T1	Participants 446 526	patients with sentinel lymph node-positive (SLN+) primary invasive breast cancer
T2	Participants 566 574	patients
T3	Participants 621 629	patients
T4	Participants 939 979	Patients with SLN+ primary breast cancer
T5	Participants 1296 1304	patients
T6	Participants 1338 1371	standard treatment = 244 patients
T7	Participants 1388 1419	investigational treatment = 230
T8	Participants 1529 1537	patients
T9	Participants 1722 1730	patients
T10	Participants 2095 2107	Six patients
T11	Participants 2009 2017	patients
T12	Participants 2059 2067	patients
T13	Participants 2128 2139	13 patients
T14	Participants 2359 2421	premenopausal patients and patients with larger (pT2-3) tumors
